SEPN Septerna, Inc.
USHealthcareAs of 2026-10-08
Why SEPN matters now
Septerna, Inc. (SEPN) is a US stock in Healthcare. The latest InvestLog snapshot shows $36.90 with +2.50% on the session and $1.66B in market capitalization; recent performance reads 1-month +36.44% and YTD +29.73%.
The latest financial table shown here is Q1 2026, with revenue of $26.5M, net income of $-8.6M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 6.6%.
The latest indexable market news headline is "CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $52.50; recent insider activity includes Shaikhly Samira filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.28
P/S
22.56
EV/EBITDA
-30.35
DCF Value
$-20.64
FCF Yield
6.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-77.1%
Net Margin
-49.9%
ROE
-9.4%
ROA
-6.3%
ROIC
-11.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $26.5M | $-8.6M | $-0.19 |
| Q4 2025 | $24.1M | $-10.7M | $-0.24 |
| FY 2025 | $46.0M | $-48.9M | $-1.10 |
| Q3 2025 | $21.5M | $8.2M | $0.18 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$50.00
Target (Median)
$52.50
Target Range
$35.00 - $60.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.38
Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.